Why Lexicon Pharmaceuticals Is Down 11% Today
After Lexicon Pharmaceuticals (NASDAQ: LXRX) announced yesterday the publication of phase 3 results for its lead diabetes drug, sotagliflozin, in the New England Journal of Medicine, its shares are losing 11% of their value at 11:45 a.m. EDT.
Sotagliflozin is a novel diabetes drug that attempts to improve glycemic control by targeting both SGLT1 and SGLT2 for the first time.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Sanofi S.A. ADR Stock
€48.20
-1.240%
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Sanofi S.A. ADR.
As a result the target price of 55 € shows a slightly positive potential of 14.11% compared to the current price of 48.2 € for Sanofi S.A. ADR.
